Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation

被引:23
作者
McGlasson, DL
Kaczor, DA
Krasuski, RA
Campbell, CL
Kostur, MR
Adinaro, JT
机构
[1] Wilford Hall USAF Med Ctr, Clin Res Squadron 59, Lackland AFB, TX 78236 USA
[2] Diagnost Stago Inc, Tech Serv, Parsippany, NJ USA
关键词
unfractionated heparin; enoxaparin; low molecular weight heparin; anti-activated factor X; activated partial thromboplastin time; anticoagulant; CTAD; sodium citrate;
D O I
10.1097/01.mbc.0000164424.90545.6e
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to determine whether the anti-activated factor X (anti-FXa) assay is less affected by pre-analytical variables in monitoring patients on unfractionated heparin (UFH) and low molecular weight heparin (LMWH) than the activated partial thromboplastin time (aPTT). Forty-six subjects receiving either enoxaparin (LMWH) or UFH were randomly selected. Each study subject had six vacutainer tubes (3.8% sodium citrate, 3.2% sodium citrate) drawn by an atraumatic venipuncture. One tube from each set had a blood to anticoagulant ratio of 9 : 1. The other tube had an intentional 'short-draw' of approximately 6 : 1 blood to anticoagulant ratio. All specimens had an aPTT and a chromogenic anti-FXa assay performed on each specimen regardless of heparin type. The aPTT assay mean with the 3.8% sodium citrate tube short-draw tube was statistically different from the other aPTT assays (P = 0.06). However, all six of the mean anti-FXa assays for the UFH and LMWH heparin subjects were not statistically or clinically different (analysis of variance, P = 0.9878 for UFH and P = 0.9060 for LMWH). The intentional short-draw tube did not affect the anti-FXa assay regardless of the anticoagulant. The anti-FXa assay appears to be a better method for monitoring heparin subjects than the aPTT due to the lack of effect of pre-nalytical variables. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:173 / 176
页数:4
相关论文
共 17 条
[1]   Minimum specimen volume requirements for routine coagulation testing - Dependence on citrate concentration [J].
Adcock, DM ;
Kressin, DC ;
Marlar, RA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 109 (05) :595-599
[2]  
Adcock DM, 1997, AM J CLIN PATHOL, V107, P105
[3]  
Adler Brian K, 2004, Clin Lab Sci, V17, P113
[4]  
BECTONDICKINSON, 2001, VS5816 BD VAC SYST, P1
[5]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[6]  
CANTON MM, 1997, CLIN HEMATOLOGY FUND, P581
[7]   How to deliver quality results in the coagulation laboratory: Commonly asked questions [J].
Castellone, D .
LABORATORY MEDICINE, 2004, 35 (04) :208-+
[8]  
CASTELLONE D, 2004, ADVANCE, V13, P50
[9]  
EVANS EW, 2000, CLIN HEMOS REV, V14, P8
[10]  
FRISTSMA GA, 2002, HEMATOLOGY CLIN PRIN, P738